• Lung Cancer Group Cologne
  • Contact
  • Privacy Policy
  • English
    • Deutsch (German)
Netzwerk Genomische Medizin Lungenkrebs
  • Doctors
    • Information
      • Service invoicing
      • Service invoicing for pathologists
    • Clinical trials
      • Lung Cancer Study Group
      • General information
  • Patients
    • General information
      • Driver mutations in lung cancer
      • New immunotherapeutic therapeutic approaches
      • Second Opinion service
      • Molecular Diagnostics
      • New therapeutic approaches from genomic research
    • Clinical trials
      • Lung Cancer Study Group
      • General information
      • What is a clinical trial?
      • Participation in a trial
    • Find doctors nearby
  • The Network
    • Aims
    • Funding
    • Our team
    • Publications
    • Related links
  • Driver mutations
  • Diagnostics
  • Hybrid-capture
  • Fast-track analysis for first-line treatment
Select Page

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort.

Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Milia JD, Thomas RK, Gautschi O.

Journal: J. Clin Oncol.
Published: 20. March 2015

  • © 2016-2018 Network Genomic Medicine (NGM)
  • Contact
  • Imprint
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress